{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:02:55Z","timestamp":1780700575188,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofpsychiatricresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jpsychires.2013.12.013","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T01:46:24Z","timestamp":1389059184000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia"],"prefix":"10.1016","volume":"51","author":[{"given":"Izaskun","family":"Villar-Men\u00e9ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"D\u00edaz-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Blanch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Albasanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Pereira-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Maria","family":"Planchat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidre","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairena","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Barrachina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2013.12.013_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ajmg.b.30140","article-title":"Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report","volume":"134B","author":"Abdolmaleky","year":"2005","journal-title":"Am J Med Genet Neuropsychiatr Genet"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2710.2000.00273.x","article-title":"Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions","volume":"25","author":"Akhondzadeh","year":"2000","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pnpbp.2004.11.008","article-title":"Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial","volume":"29","author":"Akhondzadeh","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-3639.2007.00112.x","article-title":"Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease","volume":"18","author":"Albasanz","year":"2008","journal-title":"Brain Pathol"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib5","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.neuropharm.2011.01.048","article-title":"Adenosine hypothesis of schizophrenia\u2013opportunities for pharmacotherapy","volume":"62","author":"Boison","year":"2012","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v66n0209","article-title":"A\u00a0clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia","volume":"66","author":"Brunstein","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neulet.2006.11.071","article-title":"Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment","volume":"414","author":"Brunstein","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0165-1781(89)90148-0","article-title":"The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia","volume":"27","author":"Buchanan","year":"1989","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1471-4159.2010.06928.x","article-title":"DNA methylation and Yin Yang-1 repress adenosine A2A receptor levels in human brain","volume":"115","author":"Buira","year":"2010","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1471-4159.2009.06538.x","article-title":"DNA methylation regulates adenosine A(2A) receptor cell surface expression levels","volume":"112","author":"Buira","year":"2010","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s004390050366","article-title":"Mapping of the human adenosine A2a receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region","volume":"99","author":"Deckert","year":"1997","journal-title":"Hum Genet"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00001756-200303030-00003","article-title":"Up-regulation of striatal adenosine A(2A) receptors in schizophrenia","volume":"14","author":"Deckert","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib15","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/hmg\/ddr416","article-title":"Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder","volume":"20","author":"Dempster","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2008.12.028","article-title":"A\u00a0double-blind trial of adjunctive allopurinol for schizophrenia","volume":"109","author":"Dickerson","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1345\/aph.18215","article-title":"Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists","volume":"33","author":"Dixon","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s002130050380","article-title":"Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia","volume":"133","author":"Ferr\u00e9","year":"1997","journal-title":"Psychopharmacol Berl"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10561-008-9077-0","article-title":"Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies","volume":"9","author":"Ferrer","year":"2008","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pneurobio.2012.03.005","article-title":"Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia","volume":"97","author":"Ferrer","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.nbd.2011.12.008","article-title":"Epigenetic and post-transcriptional dysregulation of gene expression in schizophrenia and related disease","volume":"46","author":"Gavin","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/YPG.0b013e3283328e26","article-title":"Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population","volume":"19","author":"Gotoh","year":"2009","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4161\/epi.4.3.8534","article-title":"From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia","volume":"4","author":"Grayson","year":"2009","journal-title":"Epigenetics"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/npp.2012.125","article-title":"The dynamics of DNA methylation in schizophrenia and related psychiatric disorders","volume":"38","author":"Grayson","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tips.2008.10.010","article-title":"Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling","volume":"30","author":"Guidotti","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib27","series-title":"Abnormal Involuntary Movement Scale (AIMS). ECDEU assessment manual of psychopharmacology","first-page":"534","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jpsychires.2010.02.006","article-title":"Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality","volume":"44","author":"Hohoff","year":"2010","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.parkreldis.2008.12.006","article-title":"Adenosine, adenosine A2A antagonists, and Parkinson's disease","volume":"15","author":"Jenner","year":"2009","journal-title":"Park Rel Disord"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2013.01.022","article-title":"Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia","volume":"146","author":"Kozielska","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1124\/mol.106.030635","article-title":"DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes","volume":"71","author":"Kundakovic","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0006-8993(98)00840-3","article-title":"An increase in [3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics","volume":"808","author":"Kurumaji","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1054\/mehy.1999.0003","article-title":"Schizophrenia: a purinergic hypothesis","volume":"54","author":"Lara","year":"2000","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1124\/mol.106.033266","article-title":"DNA (cytosine-5) methyltransferase inhibitors: a potential therapeutic agent for schizophrenia","volume":"71","author":"Levenson","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ajhg.2008.01.008","article-title":"Epigenomic profiling reveals DNA-methylation changes associated with major psychosis","volume":"82","author":"Mill","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/syn.21573","article-title":"Differential effects of age on human striatal adenosine A1 and A(2A) receptors","volume":"66","author":"Mishina","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1017\/S0033291708004716","article-title":"Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review","volume":"39","author":"Pappa","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib41","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1046\/j.1471-4159.1995.65052057.x","article-title":"Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia","volume":"65","author":"Parsons","year":"1995","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0920-9964(00)00071-2","article-title":"How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment","volume":"49","author":"Peralta","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib43","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/mds.23050","article-title":"Motor behavior abnormalities in drug-na\u00efve patients with schizophrenia spectrum disorders","volume":"25","author":"Peralta","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib44","article-title":"Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs","author":"Peralta","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuron.2006.09.015","article-title":"Neurobiology of schizophrenia","volume":"52","author":"Ross","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib47","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1172\/JCI62378","article-title":"Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia","volume":"122","author":"Shen","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2007.07.003","article-title":"Methylation status of the reelin promoter region in the brain of schizophrenic patients","volume":"63","author":"Tochigi","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1073\/pnas.2637013100","article-title":"DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains","volume":"101","author":"Veldic","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12017-013-8219-0","article-title":"Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease","volume":"15","author":"Villar-Men\u00e9ndez","year":"2013","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-011-2315-3","article-title":"Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling","volume":"218","author":"Wonodi","year":"2011","journal-title":"Psychopharmacol Berl"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.psychres.2012.04.021","article-title":"Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients","volume":"200","author":"Zhang","year":"2012","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jpsychires.2013.12.013_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2009.03.020","article-title":"An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes","volume":"111","author":"Zhubi","year":"2009","journal-title":"Schizophr Res"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395613003889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395613003889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:27:27Z","timestamp":1746098847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395613003889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":54,"alternative-id":["S0022395613003889"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2013.12.013","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2013.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}